Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Celgene
Celgene
Bristol-Myers Squibb's Q4 Earnings Update Shows Why It Needs Celgene
Motley Fool
Sun, 01/27/19 - 12:03 pm
Bristol-Myers Squibb
earnings
M&A
Celgene
BMS talks up Celgene merger to divert Opdivo disappointment
Fierce Pharma
Fri, 01/25/19 - 12:08 am
Bristol-Myers Squibb
Celgene
Opdivo
Yervoy
A flashy 2019 start to pharma M&A, but will it last?
Biopharma Dive
Tue, 01/22/19 - 11:55 pm
M&A
Celgene
Bristol-Myers Squibb
Eli Lilly
Loxo Oncology
Celgene, sold for $74 billion, leaves a legacy of chutzpah in science and drug pricing
Stat
Tue, 01/22/19 - 11:38 am
Celgene
drug pricing
M&A
Bristol-Myers Squibb
3 Potential New Drugs Held Up by the Shutdown
Motley Fool
Sat, 01/19/19 - 06:35 pm
FDA
government shutdown
Aimmune Therapeutics
AR 101
Celgene
fedratinib
Bristol-Myers Squibb
ozanimod
Celgene strikes Obsidian deal to boost CAR-T options
Fierce Biotech
Fri, 01/18/19 - 11:18 am
Celgene
Obsidian Therapeutics
CAR-T
Ahead of Bristol Myers purchase, Celgene partners with Boston cancer startup
Bizjournals
Fri, 01/18/19 - 10:20 am
Celgene
drug development
Kyn Therapautics
cancer
Acceleron, Stemline price upsized follow-ons
BioCentury
Wed, 01/16/19 - 11:57 am
Acceleron
Stemline Therapeutics
Celgene
Elzonris tagraxofusp-erzs
Smaller groups await Bristol-Myers Squelgene fallout
EP Vantage
Wed, 01/16/19 - 11:53 am
M&A
Bristol-Myers Squibb
Celgene
Vividion Therapeutics
Evotec
Prothena
Anokion
Skyhawk Therapeutics
Dragonfly Therapeutics
BeiGene
Agios Pharmaceuticals
Jounce Therapeutics
Congressmen to regulators: BMS-Celgene merger will stifle competition and raise drug prices
Fierce Pharma
Tue, 01/15/19 - 11:25 am
US Congress
M&A
Bristol-Myers Squibb
Celgene
drug pricing
NASH Space in Focus in 2019 as Firms Look to Diversify
Yahoo/Zacks.com
Sun, 01/13/19 - 11:32 am
NASH
Gilead Sciences
Merck
Roche
Novartis
Jecure Therapeutics
Pfizer
Celgene
Eli Lilly
JPM recap: Must-reads of the week, from FDA to IPO to M&A and more
Fierce Pharma
Fri, 01/11/19 - 10:25 am
JPMHC 2019
Merck
FDA
M&A
Celgene
Bristol-Myers Squibb
Genevant
IPOs
Eli Lilly
Novartis
GSK
Teva Pharmaceutical
Alexion
Pear Therapeutics
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
Xconomy
Fri, 01/11/19 - 09:58 am
Celgene
M&A
Juno Therapeutics
Kite Therapeutics
Bluebird Bio
Agios Pharmaceuticals
Jounce Therapeutics
BieGene
Acceleron
Day One of JPM Brings Excitement and Promise for a New Year in Biotech and Pharma
BioSpace
Wed, 01/9/19 - 09:40 am
JPMHC 2019
M&A
Eli Lilly
Loxo Oncology
SAGE Therapeutics
Sanofi
Regeneron
Bristol-Myers Squibb
Celgene
Novartis
Gilead Sciences
3 Things Bristol-Myers Squibb Understands About Celgene That the Market Hasn't
Motley Fool
Tue, 01/8/19 - 12:43 am
Celgene
Bristol-Myers Squibb
M&A
JPMHC 2019
Celgene invested $30M in NantCell weeks before BMS bid
BioCentury
Tue, 01/8/19 - 12:41 am
Celgene
NantCell
Bristol-Myers Squibb
M&A
Why the Bristol-Myers Squibb Acquisition Is a Bad Deal for Celgene
Motley Fool
Sun, 01/6/19 - 11:08 pm
Bristol-Myers Squibb
Celgene
M&A
After Bristol-Myers Squibb Buys Celgene What's Next? JP Morgan's Conference Will Answer That
Forbes
Sat, 01/5/19 - 03:04 pm
Celgene
Bristol-Myers Squibb
M&A
JPMHC 2019
BMS CEO Giovanni Caforio Lays out Reasoning for $74 Billion Acquisition of Celgene
BioSpace
Sat, 01/5/19 - 03:08 pm
Bristol-Myers Squibb
M&A
Giovanni Caforio
Celgene
Could Gilead, Amgen and AbbVie follow Bristol-Myers into megadeal territory?
Fierce Pharma
Sat, 01/5/19 - 01:34 pm
M&A
Bristol-Myers Squibb
Celgene
Gilead Sciences
AbbVie
Amgen
Pages
« first
‹ previous
…
5
6
7
8
9
10
11
12
13
…
next ›
last »